摘要
目的:对比观察阿昔莫司与阿托伐他汀对血浆脂蛋白(a)[lipoprotein(a),Lp(a)]水平的影响,并探讨其作用机制。方法:将血浆Lp(a)水平>300 mg/L的患者213例随机分为阿昔莫司治疗组(n=100),给予阿昔莫司250 mg,2次/d,口服,阿托伐他汀治疗组(n=113),口服阿托伐他汀10 mg,每晚1次,服药前及服药第4 w和第8 w后监测血浆Lp(a)的血浆水平。结果:服药后2组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、Lp(a)的血浆水平均明显降低(P<0.0001),高密度脂蛋白胆固醇(HDL-C)轻度升高(P>0.05)。服药4 w后,阿昔莫司组Lp(a)水平降至(410.00±130.00)mg/L,较服药前下降12.77%;阿托伐他汀组Lp(a)水平降至(460.00±130.00)mg/L,较服药前下降4.17%;2组Lp(a)水平比较差异有统计学意义(P<0.0001)。服药8周后,阿昔莫司组Lp(a)水平平均降至(370.00±120.00)mg/L,较服药前下降21.28%;阿托伐他汀组Lp(a)水平降至(440.00±120.00)mg/L,较服药前下降8.33%;2组Lp(a)水平比较差异有统计学意义(P<0.0001)。结论:阿昔莫司降Lp(a)的疗效明显优于阿托伐他汀。
Objective：To observe the effect of acipimox and atorvastatin on the serum lipoprotein（a） and to explore their individual mechanisms.Methods：Of 213 patients whose level of serum lipoprotein（a） was above 0.3mg/dl,100 cases were randomly distributed to the acipimox group,and another 113 cases were randomly distributed to the atorvastatin group.The patients were orally treated by the acipimox 250 mg bid and atorvastatin 10mg qn separately.Subsequently,the survey of serum level of lipoprotein（a） was carried out before the therapy and after 4 and 8 weeks respectively to evaluate their effects.Results：After therapy,the serum level of total cholesterol（TC）,triglyceride（TG）,low density lipoprotein cholesterol（LDL-C） and lipoprotein（a） was significantly decreased in both two groups（P 0.0001）,and the serum level of high density lipoprotein cholesterol（HDL-C） was slightly elevated（P 0.05）.After 4 weeks,the Lp（a） level was averagely decreased to（410.00 ± 130.00） mg/L in the acipimox group,and to（460.00 ± 130.00） mg/L in the atorvastatin group respectively,which lowered 12.77% and 4.17% respectively in contrast to the pre-therapy.The differences on the Lp（a） level had statistical significance between two groups（P 0.0001）.After 8 weeks,the Lp（a） level was averagely decreased to（370.00 ± 120.00）mg/L in the acipimox group,and to（440.00 ± 120.00） mg/L in the atorvastatin group respectively,which lowered 21.28% and 8.33% respectively in contrast to the pre-therapy.The differences on the Lp（a） level had statistical significance between two groups（P 0.0001）.Conclusion：Acipimox is superior to atorvastatin in lowering Lp（a） level with more striking clinical outcomes.
出处
《心肺血管病杂志》
CAS
2011年第1期4-7,共4页
Journal of Cardiovascular and Pulmonary Diseases
作者简介
通信作者：李艳芳，E—mail：liyf101@sohu．com
